Biotech Profile
Citius Pharmaceuticals – From Late-Stage Development to Commercial Launch with FDA-Approved LYMPHIR™
New Jersey biotech Citius Pharmaceuticals is transitioning from a development-stage company to revenue generation as it prepares to commercially launch LYMPHIR™, the only FDA-approved IL-2R-targeted systemic therapy for cutaneous T-cell lymphoma, in Q4 2025. In this interview, the CEO Leonard
10 October 2025